-+ 0.00%
-+ 0.00%
-+ 0.00%

Bellevue says obesity, diabetes drug market shifts focus to patient adherence at ADA 2026

PUBT·06/09/2026 08:50:25
Listen to the news
Bellevue says obesity, diabetes drug market shifts focus to patient adherence at ADA 2026
  • Bellevue Group AG flagged a shift in obesity and diabetes drug development from efficacy toward access and long-term patient adherence.
  • Eli Lilly’s retatrutide reinforced its lead in obesity; higher doses showed up to 30% weight loss, while 4 mg targeted fewer side effects.
  • Amylin-based therapies gained momentum; Lilly’s eloralintide showed about 20% weight loss, supported by Novo Nordisk’s CagriSema diabetes data.
  • Oral semaglutide adherence looks challenged by dosing requirements, while monthly dosing programs such as Pfizer’s could improve persistence.
  • Dexcom’s CONNECT data supported broader CGM use in Type 2 diabetes without insulin, potentially expanding Medicare coverage; Insulet’s Omnipod 5 showed strong STRIVE results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bellevue Group AG published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.